Age-Related Macular Degeneration Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies - Opthea, Kodiak, Outlook, Apellis, Alkeus, Iveric Bio, Novartis, Luxa Biotechnology, AstraZeneca, Annexon, REGENXBIO

New York, USA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Age-Related Macular Degeneration Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies - Opthea, Kodiak, Outlook, Apellis, Alkeus, Iveric Bio, Novartis, Luxa Biotechnology, AstraZeneca, Annexon, REGENXBIO

The overall market of age-related macular degeneration (AMD) is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapies, the treatment market of Wet-AMD and Dry-AMD is supposed to boost in the forecasted period (2023–2032).

DelveInsight’s Age-Related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, age-related macular degeneration emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Age-Related Macular Degeneration Market Report

• As per DelveInsight’s analysis, the age-related macular degeneration market size was found to be approximately USD 9.4 billion in 2022 and it is anticipated to grow at a significant CAGR by 2032.
• As per the DelveInsight estimates, in the year 2022, the total prevalent cases of AMD were approximately 53 million in the 7MM, which might increase at a decent CAGR by 2032. 
• Leading age-related macular degeneration companies such as Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Evergreen Therapeutics, Alkeus Pharmaceuticals, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics, and others are developing novel age-related macular degeneration drugs that can be available in the age-related macular degeneration market in the coming years.
• Some of the key therapies for age-related macular degeneration treatment include OPT-302, KSI-301, RGX-314, AKST4290, Zimura, EG-301, Pegcetacoplan, Gildeuretinol (ALK-001), RBM-007, Lytenava (Bevacizumab-vikg), UBX1325, PAN-90806, CLS-AX (Axitinib), Danicopan (ALXN2040), ALK-001, Elamipretide, OpRegen, CPCB-RPE1, Luminate (Risuteganib), ANX007, NGM621, LNP023 (Iptacopan), IONIS-FB-LRx, Pegcetacoplan, Zimura (Avacincaptad Pegol), GT005, RPESC-RPE-4W, GEM103, and others. 

Discover which therapies are expected to grab the major age-related macular degeneration market share @ Age-Related Macular Degeneration Market Report

Age-Related Macular Degeneration Overview

Age-Related Macular Degeneration (AMD) is a common eye condition that primarily affects individuals over the age of 50, leading to progressive vision loss in the central part of the retina known as the macula. This degenerative disorder is a major cause of visual impairment and blindness among older adults. The exact causes of AMD are not fully understood, but both genetic and environmental factors appear to play a significant role. Smoking, high blood pressure, obesity, and a diet low in certain nutrients (such as antioxidants and omega-3 fatty acids) have been associated with an increased risk of developing AMD. Genetics also seem to contribute, with certain gene variants being linked to a higher susceptibility.

Symptoms of AMD often develop gradually and may include blurry or distorted central vision, difficulty reading or recognizing faces, and the appearance of dark or empty spots in the center of one's visual field. Peripheral vision is generally unaffected, allowing individuals to maintain some level of functional vision. Diagnosing AMD typically involves a comprehensive eye examination. This may include visual acuity tests, dilated eye exams to examine the retina and macula, and specialized imaging techniques such as optical coherence tomography to assess the layers of the retina and detect any abnormalities.

Age-Related Macular Degeneration Epidemiology Segmentation

The age-related macular degeneration epidemiology section provides insights into the historical and current age-related macular degeneration patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The age-related macular degeneration market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalent Cases of Age-related Macular Degeneration
• Total Diagnosed Prevalent Cases of Age-related Macular Degeneration
• Type-specific Diagnosed Prevalent Cases of AMD
• Total Age-specific Cases of Wet AMD, and Dry AMD 
• Total Diagnosed Dry AMD Cases by Stages
• Total Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment

Download the report to understand which factors are driving age-related macular degeneration epidemiology trends @ Age-Related Macular Degeneration Epidemiological Insights

Age-Related Macular Degeneration Treatment Market 

Age-related macular degeneration (AMD) treatment encompasses a range of approaches aimed at managing this progressive eye condition, which affects the central portion of the retina, known as the macula, and can lead to severe vision loss in older adults. The treatment options for AMD vary based on the type and severity of the disease. For early-stage AMD, lifestyle modifications like adopting a healthy diet rich in antioxidants, maintaining regular exercise, and avoiding smoking are often recommended to reduce the risk of progression. Nutritional supplements containing vitamins and minerals such as vitamin C, vitamin E, zinc, copper, and antioxidants like lutein and zeaxanthin have shown potential in slowing the advancement of AMD.

In some cases of AMD, particularly the more advanced “wet” AMD characterized by abnormal blood vessel growth, targeted therapies such as anti-VEGF (vascular endothelial growth factor) injections are employed to inhibit vessel growth and preserve vision. These injections are administered directly into the eye and can help slow down or even stabilize vision loss by reducing the leakage of fluid and blood from the abnormal vessels. Moreover, photodynamic therapy (PDT) is another treatment option for specific cases of wet AMD, which involves a combination of light-sensitive medication and laser therapy to target and destroy abnormal blood vessels.

Ongoing research continues to explore innovative treatments, including potential regenerative therapies that aim to replace damaged cells in the macula and restore visual function. Gene therapy and stem cell treatments hold promise in this regard, although they are still in experimental stages. Regular eye examinations are essential for the early detection of AMD, enabling timely intervention and better management. As our understanding of AMD advances, the focus remains on improving treatment strategies to enhance the quality of life for individuals affected by this condition.

To know more about age-related macular degeneration treatment, visit @ Age-Related Macular Degeneration Treatment Drugs 

Key Age-Related Macular Degeneration Therapies and Companies

• OPT-302: Opthea Limited
• KSI-301: Kodiak Sciences Inc.
• RGX-314: REGENXBIO
• AKST4290: Alkahest Inc
• Zimura: Iveric Bio
• EG-301: Evergreen Therapeutics
• Pegcetacoplan: Apellis Pharmaceuticals
• Gildeuretinol (ALK-001): Alkeus Pharmaceuticals
• RBM-007: Ribomic USA Inc
• Lytenava (Bevacizumab-vikg): Outlook Therapeutics, Inc.
• UBX1325: Unity Biotechnology, Inc
• PAN-90806: PanOptica, Inc.
• CLS-AX (Axitinib): Clearside Biomedical
• Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
• ALK-001: Alkeus Pharmaceuticals
• Elamipretide: Stealth BioTherapeutics
• OpRegen: CellCure Neurosciences
• CPCB-RPE1: Regenerative Patch Technologies
• Luminate (Risuteganib): Allegro Ophthalmics
• ANX007: Annexon Biosciences
• NGM621: NGM Biopharmaceuticals
• LNP023 (Iptacopan): Novartis
• IONIS-FB-LRx: Ionis Pharmaceuticals
• Pegcetacoplan: Apellis Pharmaceuticals
• Zimura (Avacincaptad Pegol): Iveric Bio
• GT005: Gyroscope Therapeutics and Novartis
• RPESC-RPE-4W: Luxa Biotechnology
• GEM103: Gemini Therapeutics

Learn more about the FDA-approved drugs for age-related macular degeneration @ Drugs for Age-Related Macular Degeneration Treatment 

Age-Related Macular Degeneration Market Dynamics

Age-related macular degeneration market dynamics are undergoing significant shifts as the global population ages and healthcare technologies advance. With AMD being a leading cause of vision impairment in older adults, the demand for innovative treatments and interventions is on the rise. Pharmaceutical companies and biotech firms are heavily invested in researching and developing novel therapies, including anti-VEGF drugs and gene therapies, to slow down or halt the progression of this degenerative disease. As a result, the AMD market is witnessing intensified competition, leading to improved treatment options and potential cost reductions. 

Moreover, collaborations between research institutions, medical organizations, and industry players are fostering knowledge exchange and facilitating the development of personalized approaches to AMD management. In addition, the advent of precision medicine and the understanding of individual genetic susceptibilities have propelled the development of targeted therapies, ushering in an era of personalized AMD treatments. Genetic editing technologies, such as CRISPR-Cas9, offer the potential to correct underlying genetic mutations responsible for certain forms of AMD, heralding a new frontier in therapeutic possibilities.

However, the AMD market landscape is not devoid of challenges. The competitive AMD market is marked by pricing pressures, reimbursement uncertainties, and regulatory intricacies that impact the accessibility and affordability of novel therapies. Striking a balance between innovation and patient-centric care remains an ongoing concern, with stakeholders working collaboratively to find sustainable solutions.

Inadequate awareness and understanding of AMD among healthcare professionals and the general population present another significant barrier. Delayed diagnosis and lack of early intervention can lead to irreversible vision loss. Thus, comprehensive educational campaigns are imperative to empower individuals to recognize AMD symptoms, seek timely medical attention, and make informed treatment decisions. Geographical disparities and unequal access to healthcare further exacerbate the challenges. Rural and underserved populations may struggle to access specialized AMD care, including advanced diagnostic tools and cutting-edge therapies, perpetuating disparities in health outcomes.

Scope of the Age-Related Macular Degeneration Market Report

• Therapeutic Assessment: Age-Related Macular Degeneration current marketed and emerging therapies
• Age-Related Macular Degeneration Market Dynamics: Attribute Analysis of Emerging Age-Related Macular Degeneration Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Age-Related Macular Degeneration Market Access and Reimbursement

Discover more about age-related macular degeneration drugs in development @ Age-Related Macular Degeneration Clinical Trials

Table of Contents

Related Reports

Age-related Macular Degeneration Epidemiology

Age-related Macular Degeneration Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted age-related macular degeneration epidemiology in the 7MM.

Age-related Macular Degeneration Pipeline

Age-related Macular Degeneration Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key age-related macular degeneration companies including Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, among others.

Wet Age-related Macular Degeneration Market

Wet Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Wet AMD companies including Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Aerie Pharmaceuticals, Ashvattha Therapeutics, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Adverum Biotechnologies, TOT Biopharm, 4D Molecular Therapeutics, Abpro Corporation, Novelty Nobility, Kala Pharmaceuticals, Surrozen, Eyevensys, Ocugen, Exonate, among others.

Dry Age-related Macular Degeneration Market

Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Dry AMD companies including Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, among others.

Wet Age-related Macular Degeneration Pipeline

Wet Age-related Macular Degeneration Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Wet AMD companies including Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Aerie Pharmaceuticals, Ashvattha Therapeutics, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Adverum Biotechnologies, TOT Biopharm, 4D Molecular Therapeutics, Abpro Corporation, Novelty Nobility, Kala Pharmaceuticals, Surrozen, Eyevensys, Ocugen, Exonate, among others. 

Dry Age-related Macular Degeneration Pipeline

Dry Age-related Macular Degeneration Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Dry AMD companies including Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, among others.

Other Trending Reports

Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter